Abstract
AbstractDrug delivery technology has advanced significantly over >50 years, and has produced remarkable innovation, countless publications and conferences, and generations of talented and creative scientists. However, a critical review of the current state-of-the-art reveals that the translation of clever and sophisticated drug delivery technologies into products, which satisfy important, unmet medical needs and have been approved by the regulatory agencies, has - given the investment made in terms of time and money - been relatively limited. Here, this point of view is illustrated using a case study of technology for drug delivery into and through the skin and aims: to examine the historical development of this field and the current state-of-the-art; to understand why the translation of drug delivery technologies into products that improve clinical outcomes has been quite slow and inefficient; and to suggest how the impact of technology may be increased and the process of concept to approved product accelerated.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Guy RH, Davis AF. Topical drug delivery. In: Griffiths CEM, Barker J, Bleiker TO, Hussain W, Simpson RC, editors. In Rook’s Textbook of Dermatology. Chichester, U.K.: John Wiley & Sons Ltd; 2024.
2. Elias PM. Epidermal barrier function: intercellular lamellar lipid structures, origin, composition and metabolism. J Control Release. 1991;15:199–208.
3. Madison KC. Barrier function of the skin: “la raison d’être” of the epidermis. J Invest Dermatol. 2003;121:231–41.
4. Kasting GB, Smith RL, Cooper ER. Effect of lipid solubility and molecular size on percutaneous absorption. In: Shroot B, Schaefer H, editors. Skin Pharmacokinetics. Basel: Karger; 1987. p. 138–53.
5. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9:165–9.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献